methyl N-[(2S,3S)-1-[2-[2-[(2R,6S)-6-[(4-chlorophenyl)sulfanylmethyl]morpholin-2-yl]ethyl]anilino]-1-oxo-3-phenyl-3-quinolin-4-ylpropan-2-yl]carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-[(2S,3S)-1-[2-[2-[(2R,6S)-6-[(4-chlorophenyl)sulfanylmethyl]morpholin-2-yl]ethyl]anilino]-1-oxo-3-phenyl-3-quinolin-4-ylpropan-2-yl]carbamate
• 化学式: C₃₉H₃₉ClN₄O₄S
• 分子量: 695.3
• InChiKey: ITHFMJRKQIKGEV-IJBFHWPPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  49
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  127
• 氢给体数：
  3
• 氢受体数：
  7

文献信息

• HIV PROTEASE INHIBITORS
  申请人：MCCAULEY John A.

  公开号：US20170217986A1

  公开（公告）日：2017-08-03

  The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z 1 , Z 2 , V 1 , V 2 , V 3 , R 6 , R 6A , and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HV protease, the inhibition of HV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

  本发明涉及Formula (I)的2,6-吗啉衍生物及其药用盐，其中Z1、Z2、V1、V2、V3、R6、R6A和X在此被定义。该发明还涉及使用该发明的2,6-吗啉衍生物来抑制HV蛋白酶、抑制HV复制、预防HIV感染、治疗HIV感染以及预防、治疗和延缓艾滋病的发作或进展的方法。这些化合物及其盐可作为药物组合物中的成分使用，可选择性地与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。
• US9994587B2
  申请人：——

  公开号：US9994587B2

  公开（公告）日：2018-06-12
• [EN] HIV PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTÉASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2015134366A1

  公开（公告）日：2015-09-11

  The present invention is directed to 2,6-morpholine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein Z1, Z2, V1, V2, V3, R6, R6A, and X are defined herein. The invention also relates to methods of using the 2,6-morpholine derivatives of the invention for the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.